Kazuhiro Asami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4826327/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A randomized phase <scp>II</scp> study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with nonâ€small cell lung cancer harboring <scp><i>EGFR</i></scp> mutations (<scp>JMTO LC12</scp> â€01). Thoracic Cancer, 2022, 13, 1827-1836.	0.8	2
2	Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations. Lung Cancer, 2013, 79, 276-282.	0.9	38
3	Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study. Clinical Lung Cancer, 2011, 12, 387-392.	1.1	50
4	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 121-128.	5.1	3,794